179 related articles for article (PubMed ID: 21864237)
1. Protein targets for anticancer gold compounds: mechanistic inferences.
Gabbiani C; Messori L
Anticancer Agents Med Chem; 2011 Dec; 11(10):929-39. PubMed ID: 21864237
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms and proposed targets for selected anticancer gold compounds.
Casini A; Messori L
Curr Top Med Chem; 2011; 11(21):2647-60. PubMed ID: 22039866
[TBL] [Abstract][Full Text] [Related]
3. Gold(III) complexes in medicinal chemistry.
Maia PI; Deflon VM; Abram U
Future Med Chem; 2014 Sep; 6(13):1515-36. PubMed ID: 25365235
[TBL] [Abstract][Full Text] [Related]
4. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.
Nobili S; Mini E; Landini I; Gabbiani C; Casini A; Messori L
Med Res Rev; 2010 May; 30(3):550-80. PubMed ID: 19634148
[TBL] [Abstract][Full Text] [Related]
5. Strategies for the biological evaluation of gold anticancer agents.
Fricker SP
Anticancer Agents Med Chem; 2011 Dec; 11(10):940-52. PubMed ID: 21864236
[TBL] [Abstract][Full Text] [Related]
6. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
[TBL] [Abstract][Full Text] [Related]
7. Proteasome versus Thioredoxin Reductase Competition as Possible Biological Targets in Antitumor Mixed Thiolate-Dithiocarbamate Gold(III) Complexes.
Quero J; Cabello S; Fuertes T; Mármol I; Laplaza R; Polo V; Gimeno MC; Rodriguez-Yoldi MJ; Cerrada E
Inorg Chem; 2018 Sep; 57(17):10832-10845. PubMed ID: 30117739
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability.
Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L
Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452
[TBL] [Abstract][Full Text] [Related]
9. Exploring the C^N^C theme: Synthesis and biological properties of tridentate cyclometalated gold(III) complexes.
Jürgens S; Scalcon V; Estrada-Ortiz N; Folda A; Tonolo F; Jandl C; Browne DL; Rigobello MP; Kühn FE; Casini A
Bioorg Med Chem; 2017 Oct; 25(20):5452-5460. PubMed ID: 28823538
[TBL] [Abstract][Full Text] [Related]
10. Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives.
Jurgens S; Kuhn FE; Casini A
Curr Med Chem; 2018 Feb; 25(4):437-461. PubMed ID: 28554319
[TBL] [Abstract][Full Text] [Related]
11. Phosphine-gold(I) compounds as anticancer agents: general description and mechanisms of action.
Lima JC; Rodriguez L
Anticancer Agents Med Chem; 2011 Dec; 11(10):921-8. PubMed ID: 21864238
[TBL] [Abstract][Full Text] [Related]
12. Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: solution behavior, reactions with model proteins, antiproliferative properties.
Maiore L; Cinellu MA; Nobili S; Landini I; Mini E; Gabbiani C; Messori L
J Inorg Biochem; 2012 Mar; 108():123-7. PubMed ID: 22173093
[TBL] [Abstract][Full Text] [Related]
13. Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles.
Massai L; Cirri D; Michelucci E; Bartoli G; Guerri A; Cinellu MA; Cocco F; Gabbiani C; Messori L
Biometals; 2016 Oct; 29(5):863-72. PubMed ID: 27476157
[TBL] [Abstract][Full Text] [Related]
14. New cyclometalated gold (III) complex targeting thioredoxin reductase: exploring as cytotoxic agents and mechanistic insights.
Abyar F; Tabrizi L
Biometals; 2020 Jun; 33(2-3):107-122. PubMed ID: 32246384
[TBL] [Abstract][Full Text] [Related]
15. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study.
Casini A; Kelter G; Gabbiani C; Cinellu MA; Minghetti G; Fregona D; Fiebig HH; Messori L
J Biol Inorg Chem; 2009 Sep; 14(7):1139-49. PubMed ID: 19543922
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cytotoxicity of selected organogold(III) compounds.
Coronnello M; Mini E; Caciagli B; Cinellu MA; Bindoli A; Gabbiani C; Messori L
J Med Chem; 2005 Oct; 48(21):6761-5. PubMed ID: 16220992
[TBL] [Abstract][Full Text] [Related]
17. Chemical biology of anticancer gold(III) and gold(I) complexes.
Zou T; Lum CT; Lok CN; Zhang JJ; Che CM
Chem Soc Rev; 2015 Dec; 44(24):8786-801. PubMed ID: 25868756
[TBL] [Abstract][Full Text] [Related]
18. A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds.
Bertrand B; Casini A
Dalton Trans; 2014 Mar; 43(11):4209-19. PubMed ID: 24225667
[TBL] [Abstract][Full Text] [Related]
19. Gold(I) complexes of water-soluble diphos-type ligands: synthesis, anticancer activity, apoptosis and thioredoxin reductase inhibition.
Wetzel C; Kunz PC; Kassack MU; Hamacher A; Böhler P; Watjen W; Ott I; Rubbiani R; Spingler B
Dalton Trans; 2011 Sep; 40(36):9212-20. PubMed ID: 21826354
[TBL] [Abstract][Full Text] [Related]
20. Medicinal Chemistry of Gold Anticancer Metallodrugs.
Casini A; Sun RW; Ott I
Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
